The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.

Heather NesbittJenny WorthingtonRachel J ErringtonLaurence H PattersonPaul J SmithStephanie R McKeownDeclan J McKenna

Published in: The Prostate (2017)

These studies provide the first evidence that OCT1002 can be an effective agent in treating hypoxic, castrate-resistant prostate tumors, either singly or in combination with established chemotherapeutics for prostate cancer.

Keyphrases

prostate cancer
radical prostatectomy
optical coherence tomography
diabetic retinopathy
benign prostatic hyperplasia
optic nerve
endothelial cells
cancer therapy
drug delivery